180 related articles for article (PubMed ID: 10656737)
1. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis.
Matsui K; Takeda K; Yu ZX; Travis WD; Moss J; Ferrans VJ
Arch Pathol Lab Med; 2000 Feb; 124(2):267-75. PubMed ID: 10656737
[TBL] [Abstract][Full Text] [Related]
2. Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features.
Ferrans VJ; Yu ZX; Nelson WK; Valencia JC; Tatsuguchi A; Avila NA; Riemenschn W; Matsui K; Travis WD; Moss J
J Nippon Med Sch; 2000 Oct; 67(5):311-29. PubMed ID: 11031360
[TBL] [Abstract][Full Text] [Related]
3. Expression of human telomerase reverse transcriptase in lymphangioleiomyomatosis.
Kumaki F; Takeda K; Yu ZX; Moss J; Ferrans VJ
Am J Respir Crit Care Med; 2002 Jul; 166(2):187-91. PubMed ID: 12119231
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy. An immunohistochemical study.
Matsui K; Takeda K; Yu ZX; Valencia J; Travis WD; Moss J; Ferrans VJ
Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):1002-9. PubMed ID: 10712355
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM).
Hayashi T; Fleming MV; Stetler-Stevenson WG; Liotta LA; Moss J; Ferrans VJ; Travis WD
Hum Pathol; 1997 Sep; 28(9):1071-8. PubMed ID: 9308732
[TBL] [Abstract][Full Text] [Related]
6. Activation of the estrogen receptor contributes to the progression of pulmonary lymphangioleiomyomatosis via matrix metalloproteinase-induced cell invasiveness.
Glassberg MK; Elliot SJ; Fritz J; Catanuto P; Potier M; Donahue R; Stetler-Stevenson W; Karl M
J Clin Endocrinol Metab; 2008 May; 93(5):1625-33. PubMed ID: 18285421
[TBL] [Abstract][Full Text] [Related]
7. Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis.
Matsumoto Y; Horiba K; Usuki J; Chu SC; Ferrans VJ; Moss J
Am J Respir Cell Mol Biol; 1999 Sep; 21(3):327-36. PubMed ID: 10460750
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor-beta 1 and extracellular matrix-associated fibronectin expression in pulmonary lymphangioleiomyomatosis.
Evans SE; Colby TV; Ryu JH; Limper AH
Chest; 2004 Mar; 125(3):1063-70. PubMed ID: 15006970
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases in blood from patients with LAM.
Odajima N; Betsuyaku T; Nasuhara Y; Inoue H; Seyama K; Nishimura M
Respir Med; 2009 Jan; 103(1):124-9. PubMed ID: 18760908
[TBL] [Abstract][Full Text] [Related]
10. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors.
Nakada M; Nakamura H; Ikeda E; Fujimoto N; Yamashita J; Sato H; Seiki M; Okada Y
Am J Pathol; 1999 Feb; 154(2):417-28. PubMed ID: 10027400
[TBL] [Abstract][Full Text] [Related]
11. Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases.
Matsui K; Tatsuguchi A; Valencia J; Yu Zx; Bechtle J; Beasley MB; Avila N; Travis WD; Moss J; Ferrans VJ
Hum Pathol; 2000 Oct; 31(10):1242-8. PubMed ID: 11070117
[TBL] [Abstract][Full Text] [Related]
12. Antibody αPEP13h reacts with lymphangioleiomyomatosis cells in lung nodules.
Valencia JC; Steagall WK; Zhang Y; Fetsch P; Abati A; Tsukada K; Billings E; Hearing VJ; Yu ZX; Pacheco-Rodriguez G; Moss J
Chest; 2015 Mar; 147(3):771-777. PubMed ID: 25411763
[TBL] [Abstract][Full Text] [Related]
13. [Pulmonary lymphangioleiomyomatosis. Morphologic and immunohistochemical findings].
Kuhnen C; Preisler K; Müller KM
Pathologe; 2001 May; 22(3):197-204. PubMed ID: 11402850
[TBL] [Abstract][Full Text] [Related]
14. Immunohistological features related to functional impairment in lymphangioleiomyomatosis.
Nascimento ECTD; Baldi BG; Mariani AW; Annoni R; Kairalla RA; Pimenta SP; da Silva LFF; Carvalho CRR; Dolhnikoff M
Respir Res; 2018 May; 19(1):83. PubMed ID: 29739412
[TBL] [Abstract][Full Text] [Related]
15. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas.
Nakamura H; Ueno H; Yamashita K; Shimada T; Yamamoto E; Noguchi M; Fujimoto N; Sato H; Seiki M; Okada Y
Cancer Res; 1999 Jan; 59(2):467-73. PubMed ID: 9927064
[TBL] [Abstract][Full Text] [Related]
16. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas.
Ueno H; Nakamura H; Inoue M; Imai K; Noguchi M; Sato H; Seiki M; Okada Y
Cancer Res; 1997 May; 57(10):2055-60. PubMed ID: 9158005
[TBL] [Abstract][Full Text] [Related]
17. Differential expression pattern of membrane-type matrix metalloproteinases in rheumatoid arthritis.
Pap T; Shigeyama Y; Kuchen S; Fernihough JK; Simmen B; Gay RE; Billingham M; Gay S
Arthritis Rheum; 2000 Jun; 43(6):1226-32. PubMed ID: 10857781
[TBL] [Abstract][Full Text] [Related]
18. Expression and distribution of MMPs and TIMPs in human uveal melanoma.
Lai K; Conway RM; Crouch R; Jager MJ; Madigan MC
Exp Eye Res; 2008 Jun; 86(6):936-41. PubMed ID: 18423620
[TBL] [Abstract][Full Text] [Related]
19. Renal angiomyolipoma: further immunophenotypic characterization of an expanding morphologic spectrum.
Stone CH; Lee MW; Amin MB; Yaziji H; Gown AM; Ro JY; Têtu B; Paraf F; Zarbo RJ
Arch Pathol Lab Med; 2001 Jun; 125(6):751-8. PubMed ID: 11371226
[TBL] [Abstract][Full Text] [Related]
20. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
